National Pension Service Sells 26,824 Shares of Hologic, Inc. (NASDAQ:HOLX)

National Pension Service cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 413,982 shares of the medical equipment provider’s stock after selling 26,824 shares during the quarter. National Pension Service owned approximately 0.18% of Hologic worth $29,844,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. FMR LLC increased its holdings in shares of Hologic by 64.0% in the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider’s stock worth $453,940,000 after purchasing an additional 2,174,093 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of Hologic by 32.7% in the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after purchasing an additional 544,889 shares during the last quarter. Swedbank AB increased its holdings in shares of Hologic by 18.8% in the third quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider’s stock worth $157,788,000 after purchasing an additional 306,562 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Hologic by 21.3% in the third quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider’s stock worth $110,700,000 after purchasing an additional 238,222 shares during the last quarter. Finally, Barclays PLC increased its holdings in shares of Hologic by 47.6% in the third quarter. Barclays PLC now owns 718,231 shares of the medical equipment provider’s stock worth $58,507,000 after purchasing an additional 231,578 shares during the last quarter. 94.73% of the stock is owned by institutional investors.

Hologic Stock Up 0.3 %

Shares of NASDAQ:HOLX opened at $63.38 on Friday. Hologic, Inc. has a 1 year low of $62.69 and a 1 year high of $84.67. The business has a 50 day simple moving average of $69.16 and a two-hundred day simple moving average of $75.94. The firm has a market capitalization of $14.22 billion, a PE ratio of 19.99, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts predict that Hologic, Inc. will post 4.28 EPS for the current year.

Analysts Set New Price Targets

HOLX has been the topic of several research reports. Leerink Partners cut Hologic from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $80.00 to $75.00 in a report on Thursday, February 6th. Jefferies Financial Group initiated coverage on Hologic in a research note on Tuesday, December 10th. They set a “hold” rating and a $85.00 price objective on the stock. Royal Bank of Canada reduced their price objective on Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a research note on Thursday, February 6th. Morgan Stanley reduced their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Finally, Raymond James reissued an “outperform” rating and set a $90.00 price objective (down from $95.00) on shares of Hologic in a research note on Thursday, February 6th. Ten research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $85.77.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 1.88% of the stock is owned by company insiders.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.